Table 4.
Gross Anatomy and Cystic and Fibrotic Areas in Polycystic Kidney Rats Treated with ACY-125 and Pasireotide Alone or in Combination
| Variables | Untreated | ACY-1215 | Pasireotide | ACY-1215 + Pasireotide |
|---|---|---|---|---|
| Body weight, g | ||||
| Male | 446.6 ± 38.3 | 416.3 ± 15.1 | 413.7 ± 10.7 | 418.1 ± 38.7 |
| Female | 286.7 ± 23.5 | 281.1 ± 14.9 | 282.5 ± 8.7 | 282.5 ± 14.6 |
| Liver weight, g | ||||
| Male | 26.1 ± 2.1 | 21.3 ± 1.4∗ | 19.3 ± 1.5∗ | 17.7 ± 1.2∗∗ |
| Female | 15.5 ± 1.3 | 14.5 ± 0.9∗ | 13.0 ± 0.5∗∗ | 11.7 ± 0.6∗∗∗ |
| Liver/body weight, % | ||||
| Male | 6.1 ± 0.5 | 5.1 ± 0.2∗ | 5.0 ± 0.2∗ | 4.3 ± 0.2∗∗ |
| Female | 5.6 ± 0.2 | 3.5 ± 0.3∗ | 3.4 ± 0.2∗∗ | 2.9 ± 0.2∗∗∗ |
| Kidney weight, g | ||||
| Male | 7.7 ± 0.3 | 6.7 ± 0.3∗∗ | 6.5 ± 0.2∗ | 6.0 ± 0.2∗ |
| Female | 4.0 ± 0.2 | 3.5 ± 0.2∗ | 3.4 ± 0.2∗ | 2.9 ± 0.1∗∗ |
| Kidney/body weight, % | ||||
| Male | 1.7 ± 0.1 | 1.6 ± 0.1∗ | 1.6 ± 0.1∗∗ | 1.5 ± 0.1∗∗ |
| Female | 1.4 ± 0.1 | 1.3 ± 0.1∗ | 1.2 ± 0.1∗∗ | 1.0 ± 0.1∗∗∗ |
| Hepatic cystic area, % of total parenchyma | 16.7 ± 3.4 | 11.2 ± 2.7∗∗ | 10.5 ± 1.9∗∗∗ | 9.2 ± 1.3∗∗∗ |
| Hepatic fibrotic area, % of total parenchyma | 7.6 ± 1.3 | 5.1 ± 1.0∗∗∗∗ | 5.2 ± 1.0∗∗∗ | 4.2 ± 0.9∗∗∗∗ |
| Renal cystic area, % of total parenchyma | 31.3 ± 4.5 | 23.3 ± 3.2∗∗∗∗ | 21.2 ± 2.9∗∗∗∗ | 18.8 ± 2.8∗∗∗∗ |
| Renal fibrotic area, % of total parenchyma | 2.5 ± 0.5 | 1.8 ± 0.4∗∗∗∗ | 1.7 ± 0.3∗∗∗∗ | 1.5 ± 0.2∗∗∗∗ |
Data are expressed as means ± SD.
∗P < 0.05, ∗∗P < 0.01,∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001 untreated versus with ACY-1215 alone, pasireotide alone, or ACY-1215 + pasireotide combination.